Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib Plus Venetoclax in RR-CLL
NCT03226301Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Jun 2017
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of ibrutinib, venetoclax in chronic lymphocytic leukemia (CLL), sponsored by HOVON. Started Jun 2017; status: active, not recruiting.
02
Drugs
ibrutinibvenetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03226301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03226301.